Trial
NCT06285097
A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Pfizer
Collaborators
—
Condition
Neoplasms
Intervention
PF-07820435
Why stopped
The trial was terminated for strategic business reasons; the decision was not based on any safety and/or efficacy concerns.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-09-17